Fierce Biotech reports that rumors are heating up (again!) that GSK will make as move to buy Human Genome Sciences (HGS) as the latter's stock price is down. GSK, of course, partners with HGS on its recently approved Benlysta for the treatment of lupus. With HGS stock down, analysts project that GSK coudl actually acquire the company for less than Benlysta's market value -- which would be a good deal indeed.
HGS is still chugging away at launching Benlysta -- building a commercial team to drive revenue and transform the company into a full fledged biotech -- not just a development group without a commercial product. But as a one hit wonder, without substantial revenue flowing in at the moment, HGS is vunerable to takeover and GSK is the most likely suitor. Even rumors of the takeover haven't been sufficient to bump up HGS' stock value. It may be only a matter of time.
Posted by Bruce Lehr Aug 25th 2011.